Now the same for Adelaide hospital workHave used the aid of Ai...

Now the same for Adelaide hospital work

Have used the aid of Ai to extract some transcript from the Webinar, and then more Ai to create a summary of that with particular focus on the Adelaide hospital work. What is printed below is not word for word what the CEO said, it is rather an Ai summary which is quite accurate I believe - but DYOR, do not rely on this Ai generated webinar summary to make investment decisions, best you listen to the Youtube recording instead.

here is the Ai summarised Adelaide part of it :


Adelaide Hospital Work

Ryan Soutar: Could you provide an update on the work being done at the Royal Adelaide Hospital with your Oncosil device?

Nigel Lange: Certainly, the Royal Adelaide Hospital has been a significant site for our work with the Oncosil device, particularly under Australia’s Special Access Scheme (SAS). Here's a detailed breakdown of the activities and developments at this key location:

Special Access Scheme (SAS) Treatments

Significance of the Royal Adelaide Hospital:

• The Royal Adelaide Hospital has been one of the leading institutions in Australia for administering the Oncosil treatment under the SAS. This scheme allows patients with serious conditions to access medical treatments not yet approved for general use.
• The hospital's involvement provides us with valuable clinical experience and data, contributing to our overall understanding and improvement of the Oncosil treatment protocol.

Clinical Experience and Outcomes

Patient Responses:

• The patients treated at the Royal Adelaide Hospital have shown promising responses to the Oncosil treatment. The treatment involves the direct injection of our radiotherapeutic device into pancreatic tumors, providing a targeted and potent dose of radiation.
• The clinical team at the hospital has reported positive outcomes in terms of tumor response and patient safety. These outcomes are crucial as they offer real-world evidence of the treatment's effectiveness and safety profile.

Downstaging and Resection:

• One of the notable successes at the Royal Adelaide Hospital has been the ability to downstage tumors, making previously inoperable tumors resectable. Surgical resection is the gold standard for cancer treatment, offering the best prognosis for long-term survival.
• The hospital has managed to downstage a significant number of patients, enabling surgical teams to safely resect tumors that were initially deemed too risky to operate on due to their proximity to vital vascular structures.

Collaboration and Expertise

Multidisciplinary Team:

• The success at the Royal Adelaide Hospital can be attributed to the multidisciplinary team involved in the treatment process. This team includes oncologists, interventional radiologists, surgeons, and other specialists who work together to provide comprehensive care.
• Their expertise and collaborative approach ensure that each patient receives personalized treatment, optimizing the chances of a positive outcome.

Research and Development

Data Collection and Analysis:

• The clinical data collected from the treatments at the Royal Adelaide Hospital is invaluable for our ongoing research and development efforts. It helps us refine our treatment protocols, enhance the safety and efficacy of the Oncosil device, and provides essential evidence for regulatory submissions.
• This data also supports our applications for broader regulatory approval and reimbursement, both in Australia and internationally.

Patient Monitoring and Follow-Up:

• Patients treated at the Royal Adelaide Hospital are closely monitored to assess their long-term outcomes. This includes regular follow-ups with imaging and clinical evaluations to track the progression of their disease and any potential side effects of the treatment.
• Continuous monitoring ensures that we can promptly address any issues and adjust treatment plans as necessary, further improving patient care and outcomes.

Conclusion on Adelaide Hospital Work

Nigel Lange: To summarize, the Royal Adelaide Hospital has played a pivotal role in the administration and evaluation of the Oncosil treatment under the Special Access Scheme. The positive patient responses, successful downstaging and resection of tumors, and the collaborative efforts of the multidisciplinary team underscore the significance of this work. The data and experience gained from this site are crucial for our broader clinical and regulatory strategy, helping us bring the Oncosil treatment to more patients in need.